Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma by Siegel, D S et al.
 
Vorinostat in combination with lenalidomide and dexamethasone
in patients with relapsed or refractory multiple myeloma
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Siegel, D. S., P. Richardson, M. Dimopoulos, P. Moreau, C.
Mitsiades, D. Weber, J. Houp, et al. 2014. “Vorinostat in
combination with lenalidomide and dexamethasone in patients
with relapsed or refractory multiple myeloma.” Blood Cancer
Journal 4 (4): e202. doi:10.1038/bcj.2014.23.
http://dx.doi.org/10.1038/bcj.2014.23.
Published Version doi:10.1038/bcj.2014.23
Accessed February 19, 2015 4:01:07 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12153006
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAACORRIGENDUM
Vorinostat in combination with lenalidomide and dexamethasone
in patients with relapsed or refractory multiple myeloma
DS Siegel
1,9,10, P Richardson
2,9, M Dimopoulos
3, P Moreau
4, C Mitsiades
1, D Weber
5, J Houp
6, C Gause
6, S Vuocolo
6, J Eid
6,
T Graef
7 and KC Anderson
8
Blood Cancer Journal (2014) 4, e202; doi:10.1038/bcj.2014.23; published online 11 April 2014
Correction to: Blood Cancer Journal (2014) 4, e182; doi:10.1038/
bcj.2014.1; published online 21 February 2014
Since the publication of this article, the authors have identiﬁed an
error concerning one of the author afﬁliation addresses. KC
Anderson was incorrectly afﬁliated to the following address:
‘Merck & Co. Inc., Whitehouse Station, NJ, USA’. The correct
address details are shown here.
The article has also been rectiﬁed, and now carries the correct
information.
The Authors would like to apologise for any inconvenience this
may have caused.
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